Safety Shot Management

Management Kriterienprüfungen 0/4

Safety Shot CEO ist Jarrett Boon , ernannt in Feb 2024, hat eine Amtszeit von weniger als ein Jahr. besitzt direkt 2.05% der Aktien des Unternehmens, im Wert von $965.26K . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 0.9 Jahre bzw. 1.5 Jahre.

Wichtige Informationen

Jarrett Boon

Geschäftsführender

n/a

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	n/a
Amtszeit als Geschäftsführer	less than a year
Eigentum des Geschäftsführers	2.0%
Durchschnittliche Amtszeit des Managements	less than a year
Durchschnittliche Amtszeit der Vorstandsmitglieder	1.5yrs

Jüngste Management Updates

Recent updates

Jupiter Wellness inks exclusive licensing deal with Rejoy for new prescription products

Sep 20

Jupiter Wellness agrees with drug developer to refrain from exercising convertible note rights

Jul 26

Jupiter Wellness says developing a new women’s sexual health product

Jul 06

Jupiter Wellness: Advancing CBD-Based Medical Therapeutics And Wellness Products

Nov 30

Geschäftsführer

Jarrett Boon (57 yo)

less than a year

Amtszeit

Mr. Jarrett Boon was Advisory Board Member of Mangoceuticals, Inc since January 06, 2023. He serves as Director at Safety Shot, Inc. (formerly known as Jupiter Wellness, Inc.) since October 10, 2023 and se...

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Jarrett Boon	CEO & Director	less than a year	keine Daten	2.05% $ 965.3k
Jordan Schur	President & Director	less than a year	keine Daten	0.41% $ 193.0k
Danielle Rosa-Diaz	Chief Financial Officer	less than a year	keine Daten	0% $ 0
David Sandler	Chief Operating Officer	less than a year	keine Daten	0% $ 0
Anthony Pedicelli	Director of Marketing	1.8yrs	keine Daten	keine Daten
Andy Goren	Chief Medical Officer & Member of Scientific Advisory Board	2.6yrs	keine Daten	keine Daten
Josh Wagner	Chief Revenue Officer	1.5yrs	keine Daten	keine Daten

0.9yrs

Durchschnittliche Betriebszugehörigkeit

52yo

Durchschnittliches Alter

Erfahrenes Management: SHOTDas Führungsteam des Unternehmens gilt nicht als erfahren ( 0.9 Jahre durchschnittliche Betriebszugehörigkeit), was auf ein neues Team schließen lässt.

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Jarrett Boon	CEO & Director	1.3yrs	keine Daten	2.05% $ 965.3k
Jordan Schur	President & Director	less than a year	keine Daten	0.41% $ 193.0k
Andy Goren	Chief Medical Officer & Member of Scientific Advisory Board	3.5yrs	keine Daten	keine Daten
Hector Alila	Member of Scientific Advisory Board	2.3yrs	US$25.00k	0% $ 0
Christopher Melton	Independent Director	5.4yrs	US$25.00k	0.10% $ 48.3k
Jack Brewer	Member of Advisory Board	1.3yrs	keine Daten	keine Daten
Richard Pascucci	Member of Advisory Board & Director	1.5yrs	keine Daten	0% $ 0
Miklos Gulyas	Independent Chairman	1.5yrs	keine Daten	2.05% $ 965.3k
David Long	Independent Director & Member of Advisory Board	1.4yrs	keine Daten	0% $ 0

1.5yrs

Durchschnittliche Betriebszugehörigkeit

52yo

Durchschnittliches Alter

Erfahrener Vorstand: SHOTDie Vorstandsmitglieder gelten nicht als erfahren ( 1.5 Jahre durchschnittliche Amtszeit), was auf einen neuen Vorstand hindeutet.

Unternehmensanalyse und Finanzdaten Status

Daten	Zuletzt aktualisiert (UTC-Zeit)
Unternehmensanalyse	2025/01/05 13:09
Aktienkurs zum Tagesende	2025/01/03 00:00
Gewinne	2024/09/30
Jährliche Einnahmen	2023/12/31

Datenquellen

Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.

Paket	Daten	Zeitrahmen	Beispiel US-Quelle ^*
Finanzdaten des Unternehmens	10 Jahre	Gewinn- und Verlustrechnung Kapitalflussrechnung Bilanz	SEC-Formular 10-K SEC-Formular 10-Q
Konsensschätzungen der Analysten	+3 Jahre	Finanzielle Vorausschau Kursziele der Analysten	Analysten Research Berichte Blue Matrix
Marktpreise	30 Jahre	Aktienkurse Dividenden, Splits und Aktionen	ICE-Marktdaten SEC-Formular S-1
Eigentümerschaft	10 Jahre	Top-Aktionäre Insiderhandel	SEC-Formular 4 SEC-Formular 13D
Verwaltung	10 Jahre	Das Führungsteam Direktorium	SEC-Formular 10-K SEC-Formular DEF 14A
Wichtige Entwicklungen	10 Jahre	Ankündigungen des Unternehmens	SEC-Formular 8-K

^* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige Formulare und Quellen verwendet.

Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie hier mehr.

Analysemodell und Schneeflocke

Einzelheiten zum Analysemodell, das zur Erstellung dieses Berichts verwendet wurde, finden Sie auf unserer Github-Seite. Wir haben auch Anleitungen zur Verwendung unserer Berichte und Tutorials auf Youtube.

Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.

Metriken für Industrie und Sektor

Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf .

Analysten-Quellen

Safety Shot, Inc. wird von 1 Analysten beobachtet. 0 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.

Analyst	Einrichtung
Ishan Majumdar	Baptista Research

Safety Shot Management

Management Kriterienprüfungen 0/4

Wichtige Informationen

Jüngste Management Updates

Independent Director exercised options and sold US$57m worth of stock

Safety Shot, Inc., Annual General Meeting, Jul 31, 2024

Safety Shot, Inc. Appoints David J. Long to the Board of Directors

Safety Shot, Inc Appoints Jordan Schur as President and Company Board Member

Safety Shot, Inc. Announces Chief Executive Officer Changes

Safety Shot, Inc. Appoints Danielle De Rosa as Chief Financial Officer, Effective March 1,2024

Recent updates

Safety Shot, Inc. Launches Revolutionary On-The-Go Stick Packs, Poised to Disrupt the $2 Billion Wellness Market

Independent Director exercised options and sold US$57m worth of stock

Safety Shot, Inc. has filed a Follow-on Equity Offering in the amount of $5 million.

Safety Shot, Inc. has filed a Follow-on Equity Offering in the amount of $0.49829 million.

Third quarter 2024 earnings released: US$0.21 loss per share (vs US$0.26 loss in 3Q 2023)

Safety Shot, Inc. Announces the Launch of Its Newly Rebranded and Reformulated Alcohol-Reducing Beverage, Sure Shot

Safety Shot, Inc. Rebrands as Sure Shot and Unveils a Bold New Look, Focusing on 4-Ounce Bottles and Powder Stick Packs

New major risk - Share price stability

Safety Shot, Inc. announced that it has received $3.421346 million in funding from Core 4 Capital Corp.

Safety Shot Clinical Data Results Confirm Breakthrough in Dramatic Reduction of Morning-After Symptoms Associated with Excessive Drinking

Health Check: How Prudently Does Safety Shot (NASDAQ:SHOT) Use Debt?

New major risk - Financial position

Safety Shot, Inc. to Release On-the-Go Powder Stick Packs of the First Alcohol Reducing Product

Safety Shot, Inc. announced that it expects to receive $1 million in funding

Safety Shot, Inc., Annual General Meeting, Jul 31, 2024

Safety Shot, Inc. Launch of Revolutionary Formula in New, Convenient 4-Ounce Bottles

First quarter 2024 earnings released: US$0.33 loss per share (vs US$0.051 loss in 1Q 2023)

Safety Shot, Inc. has filed a Follow-on Equity Offering in the amount of $4.999999 million.

New major risk - Revenue size

Full year 2023 earnings released: US$0.48 loss per share (vs US$0.70 loss in FY 2022)

Safety Shot, Inc. Appoints David J. Long to the Board of Directors

Safety Shot, Inc Appoints Jordan Schur as President and Company Board Member

Is Safety Shot (NASDAQ:SHOT) Using Debt In A Risky Way?

New minor risk - Market cap size

Safety Shot, Inc. Announces Chief Executive Officer Changes

Safety Shot, Inc. Appoints Danielle De Rosa as Chief Financial Officer, Effective March 1,2024

Less than half of directors are independent

Safety Shot Appoints Rich Pascucci to Its Board of Directors

Safety Shot, Inc. Announces West Coast Launch of Safety Shot

Safety Shot, Inc. announced delayed 10-Q filing

New major risk - Shareholder dilution

Safety Shot, Inc., Annual General Meeting, Dec 05, 2023

Safety Shot Inc. Announces Direct-To-Consumer Launch of Safety Shot

Safety Shot, Inc. Appoints Jarrett Boon to its Board of Directors

The Honorable Jack Brewer, M.Ed. Joins Safety Shot’s Advisory Board

Jupiter Wellness Appoints Jarrett Boon as COO

Jupiter Wellness Regains Compliance with Nasdaq Listing Rule 5550(a)(2)

Jupiter Wellness, Inc. Announces Chief Financial Officer Changes

Second quarter 2023 earnings released: US$0.013 loss per share (vs US$0.066 loss in 2Q 2022)

Jupiter Wellness, Inc. Appoints David Long to its Advisory Board

Jupiter Wellness, Inc Announces Board Appointments

Jupiter Wellness, Inc. Announces Executive Changes

New major risk - Share price stability

Jupiter Wellness, Inc. (NasdaqCM:JUPW) agreed to acquire Assets of GBB Drink Lab Inc.

First quarter 2023 earnings released: US$0.051 loss per share (vs US$0.13 loss in 1Q 2022)

Full year 2022 earnings released: US$0.69 loss per share (vs US$1.69 loss in FY 2021)

Jupiter Wellness, Inc. Appoints Hector Alila as Additional Director

Jupiter Wellness, Inc., Annual General Meeting, Dec 22, 2022

Jupiter Wellness Regains Compliance with Nasdaq Minimum Bid Price Requirement

Jupiter Wellness Regains Compliance with Nasdaq Minimum Bid Price Requirement

Third quarter 2022 earnings released: US$0.11 loss per share (vs US$0.24 loss in 3Q 2021)

Less than half of directors are independent

Jupiter Wellness, Inc. Re-Opens Enrollment in Clinical Trial Comparison of JW-100 and EUCRISA for the Treatment of Eczema

Director recently bought US$105k worth of stock

Jupiter Wellness, Inc. Initiates Clinical Trial for Potential New Treatment for Tinnitus

Jupiter Wellness to get US patent for minoxidil use in hair loss disorder

Jupiter Wellness inks exclusive licensing deal with Rejoy for new prescription products

Jupiter Wellness, Inc. Announces Board Changes, Effective September 15, 2022

Second quarter 2022 earnings released: US$0.066 loss per share (vs US$0.36 loss in 2Q 2021)

Jupiter Wellness agrees with drug developer to refrain from exercising convertible note rights

Jupiter Wellness says developing a new women’s sexual health product

Jupiter Wellness Receives Non-Compliance Notice from Nasdaq Related to Listing Rule 5635(c)

Jupiter Wellness Receives Non-Compliance Letter from Nasdaq

Jupiter Wellness, Inc. Appoints Prof. Andy Goren, MD as Chief Medical Officer

Jupiter Wellness, Inc. (NasdaqCM:JUPW) acquired Assets from Applied Biology, Inc. on June 21, 2022.

First quarter 2022 earnings released: US$0.13 loss per share (vs US$0.20 loss in 1Q 2021)

Less than half of directors are independent

Full year 2021 earnings released: US$1.69 loss per share (vs US$0.86 loss in FY 2020)

Jupiter Wellness, Inc. Announces Resignation of Ryan Allison as Chief Operating Officer